These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38106593)

  • 1. Voclosporin and the Antiviral Effect Against SARS-CoV-2 in Immunocompromised Kidney Patients.
    Arends EJ; Meziyerh S; Moes DJAR; Kamerling SWA; van der Kooy S; Ogando NS; Snijder EJ; van Hemert M; Visser LG; Feltkamp MCW; Claas ECJ; Rabelink TJ; van Kooten C; de Vries APJ; Teng YKO
    Kidney Int Rep; 2023 Dec; 8(12):2654-2664. PubMed ID: 38106593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cyclophilin-Dependent Calcineurin Inhibitor Voclosporin Inhibits SARS-CoV-2 Replication in Cell Culture.
    Ogando NS; Metscher E; Moes DJAR; Arends EJ; Tas A; Cross J; Snijder EJ; Teng YKO; de Vries APJ; van Hemert MJ
    Transpl Int; 2022; 35():10369. PubMed ID: 35812159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Journal Club: Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Phase 3 Trial.
    Rubio J; Kyttaris V
    ACR Open Rheumatol; 2021 Dec; 3(12):827-831. PubMed ID: 34463434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Rovin BH; Teng YKO; Ginzler EM; Arriens C; Caster DJ; Romero-Diaz J; Gibson K; Kaplan J; Lisk L; Navarra S; Parikh SV; Randhawa S; Solomons N; Huizinga RB
    Lancet; 2021 May; 397(10289):2070-2080. PubMed ID: 33971155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
    Rovin BH; Solomons N; Pendergraft WF; Dooley MA; Tumlin J; Romero-Diaz J; Lysenko L; Navarra SV; Huizinga RB;
    Kidney Int; 2019 Jan; 95(1):219-231. PubMed ID: 30420324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis.
    van Gelder T; Lerma E; Engelke K; Huizinga RB
    Expert Rev Clin Pharmacol; 2022 May; 15(5):515-529. PubMed ID: 35763288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A network meta-analysis of randomized controlled trials comparing the effectiveness and safety of voclosporin or tacrolimus plus mycophenolate mofetil as induction treatment for lupus nephritis.
    Lee YH; Song GG
    Z Rheumatol; 2023 Sep; 82(7):580-586. PubMed ID: 34545430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 infection in kidney transplant recipients: Experience of the italian marche region.
    Maritati F; Cerutti E; Zuccatosta L; Fiorentini A; Finale C; Ficosecco M; Cristiano F; Capestro A; Balestra E; Taruscia D; Vivarelli M; Donati A; Perna GP; Giacometti A; Tavio M; Onesta M; Di Sante L; Ranghino A
    Transpl Infect Dis; 2020 Oct; 22(5):e13377. PubMed ID: 32573895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood unconjugated bilirubin and tacrolimus are negative predictors of specific cellular immunity in kidney transplant recipients after SAR-CoV-2 inactivated vaccination.
    Zhang L; Yang J; Deng M; Xu C; Lai C; Deng X; Wang Y; Zhou Q; Liu Y; Wan L; Li P; Fang J; Hou J; Lai X; Ma F; Li N; Li G; Kong W; Zhang W; Li J; Cao M; Feng L; Chen Z; Chen L; Ji T
    Sci Rep; 2023 May; 13(1):7263. PubMed ID: 37142713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic calcineurin inhibitors tacrolimus and voclosporin: A review of off-label dermatologic uses.
    Dai A; Kim SJ
    J Am Acad Dermatol; 2024 Feb; 90(2):358-367. PubMed ID: 37307993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voclosporin: A Novel Calcineurin Inhibitor for the Treatment of Lupus Nephritis.
    McArn AC; Nixon AR; Jarrell KL
    Ann Pharmacother; 2022 Feb; ():10600280221075331. PubMed ID: 35168373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis.
    Arriens C; Teng YKO; Ginzler EM; Parikh SV; Askanase AD; Saxena A; Gibson K; Caster DJ; Atsumi T; Lisk L; Randhawa S; Gluck R; Solomons N; Huizinga RB
    Arthritis Care Res (Hoboken); 2023 Jul; 75(7):1399-1408. PubMed ID: 36039949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between PIRCHE-II scores and de novo allosensitization after reduction of immunosuppression during SARS-CoV-2 infection in kidney transplant recipients.
    Castrezana-Lopez K; Malchow R; Nilsson J; Kokkonen SM; Rho E; von Moos S; Mueller TF; Schachtner T
    Transpl Infect Dis; 2023 Apr; 25(2):e14052. PubMed ID: 36884207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of voclosporin for the treatment of lupus nephritis.
    Sin FE; Isenberg D
    Expert Opin Pharmacother; 2018 Oct; 19(14):1613-1621. PubMed ID: 30207816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early experience with COVID-19 in kidney transplantation recipients: update and review.
    González J; Ciancio G
    Int Braz J Urol; 2020 Jul; 46(suppl.1):145-155. PubMed ID: 32550702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients.
    Kolb T; Fischer S; Müller L; Lübke N; Hillebrandt J; Andrée M; Schmitz M; Schmidt C; Küçükköylü S; Koster L; Kittel M; Weiland L; Dreyling KW; Hetzel G; Adams O; Schaal H; Ivens K; Rump LC; Timm J; Stegbauer J
    Kidney360; 2021 Sep; 2(9):1491-1498. PubMed ID: 35373105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin inhibitor effects on kidney electrolyte handling and blood pressure: tacrolimus versus voclosporin.
    Wei KY; van Heugten MH; van Megen WH; van Veghel R; Rehaume LM; Cross JL; Viel JJ; van Willigenburg H; Silva PHI; Danser AHJ; de Baaij JHF; Hoorn EJ
    Nephrol Dial Transplant; 2024 May; ():. PubMed ID: 38777623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.